GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keryx Biopharmaceuticals Inc (NAS:KERX) » Definitions » Price-to-Tangible-Book

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Price-to-Tangible-Book : (As of Apr. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Keryx Biopharmaceuticals Price-to-Tangible-Book?

As of today (2024-04-26), Keryx Biopharmaceuticals's share price is $3.36. Keryx Biopharmaceuticals's Tangible Book per Share of Sep. 2018 for the quarter that ended in Sep. 2018 was $-0.48. Hence, Keryx Biopharmaceuticals's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Keryx Biopharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, Keryx Biopharmaceuticals's highest Price to Tangible Book Ratio was 133.11. The lowest was 0.00. And the median was 6.13.

KERX's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.68
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Keryx Biopharmaceuticals's share price is $3.36. Keryx Biopharmaceuticals's Book Value per Sharefor the quarter that ended in Sep. 2018 was $-0.45. Hence, Keryx Biopharmaceuticals's P/B Ratio of today is .


Keryx Biopharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Keryx Biopharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keryx Biopharmaceuticals Price-to-Tangible-Book Chart

Keryx Biopharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.34 18.67 6.34 - -

Keryx Biopharmaceuticals Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 147.92 - - - -

Competitive Comparison of Keryx Biopharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Keryx Biopharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Keryx Biopharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keryx Biopharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Keryx Biopharmaceuticals's Price-to-Tangible-Book falls into.



Keryx Biopharmaceuticals Price-to-Tangible-Book Calculation

Keryx Biopharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2018 )
=3.36/-0.477
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Keryx Biopharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.
Executives
Scott A Holmes officer: Chief Financial Officer C/O KERYX BIOPHARMACEUTICALS INC 1 MARINA PARK DR., 10TH FLOOR BOSTON MA 02210
Daniel Paul Regan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Jodie Pope Morrison director, officer: Interim CEO C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Mark J Enyedy director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Michael W Rogers director C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Baupost Group Gp, L.l.c. 10 percent owner 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Baupost Group Llc/ma director, 10 percent owner 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
Seth A Klarman 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Greg Madison director, officer: President and CEO ONE MARINA PARK DRIVE LEXINGTON MA 02210
Brian Adams officer: General Counsel and Secretary 750 LEXINGTON AVENUE, NEW YORK NY 10022
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Sak Corp 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Oliviero James F Iii officer: Chief Financial Officer C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Headlines

From GuruFocus

Keryx Pharmaceuticals Announces Upcoming Investor Presentations

By Marketwired Marketwired 05-30-2018

Baupost's Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals

By Holly LaFon Holly LaFon 05-12-2014

Why Seth Klarman Keeps Buying Keryx Biopharma

By Bram de Haas Bram de Haas 11-03-2015

Seth Klarman Raises Position in Keryx Biopharmaceuticals

By David Goodloe David Goodloe 10-21-2015